Compugen's Upcoming Participation in Stifel 2025 Healthcare Conference Highlights Industry Innovations

Compugen to Join Stifel 2025 Healthcare Conference

On November 4, 2025, Compugen Ltd. (Nasdaq: CGEN) announced that its management team will engage in a fireside chat at the Stifel 2025 Healthcare Conference in New York City. Scheduled for Tuesday, November 11, from 3:20 PM to 3:50 PM ET, this session aims to spotlight Compugen’s innovative approaches in the realm of cancer immunotherapy.

As a clinical-stage company focusing on the development of groundbreaking therapies using artificial intelligence, Compugen has pioneered the utilization of predictive computational strategies to identify drug targets and biological pathways. This strategic approach positions them at the forefront of the oncology sector, promising new avenues for responding to cancers that have historically been challenging to treat. Compugen's therapeutic pipeline includes sophisticated candidates such as COM701 and COM902, which are currently in Phase 1 clinical trials. COM701 is being explored as a potential first-in-class anti-PVRIG antibody, while COM902 targets TIGIT in the fight against solid tumors.

Compugen’s revolutionary discovery platform, named Unigen™, is driven by AI and machine learning, which greatly enhances the efficiency of identifying viable drug targets. By pinpointing specific mechanisms within the immune system, the company is paving the way for transformative therapies aimed at combating various forms of cancer.

The conference will also highlight the company’s collaboration with AstraZeneca, particularly in the development of Rilvegostomig, a PD-1/TIGIT bispecific antibody derived from COM902. This partnership underscores Compugen's commitment to advancing cancer treatment options through strategic industry alliances and innovative research.

Moreover, the company has engaged in licensing agreements with Gilead for the development of GS-0321, a high-affinity anti-IL-18 binding protein antibody, indicating its expanding influence in the biopharmaceutical sector.

Physicians and researchers attending the conference will have an opportunity to hear Compugen's insights into the future of immunotherapy and how AI/ML is shaping the next generation of cancer treatments.

For those unable to attend, the fireside chat will be streamed live on Compugen's Investor Relations page at www.cgen.com, and a replay will be accessible after the event. This engagement with investors and industry stakeholders reflects Compugen's ongoing efforts to communicate progress and innovation in therapeutic development.

As the field of cancer therapy evolves, events like the Stifel Healthcare Conference are vital for fostering dialogue and sharing groundbreaking ideas. Compugen’s participation exemplifies its strategic focus on advancing cancer treatment while leveraging cutting-edge technologies to enhance patient outcomes.

In summary, Compugen’s upcoming dialogue at the Stifel 2025 Healthcare Conference not only provides an important platform for the company to showcase its developments but also highlights the critical role of innovation in the battle against cancer. As they prepare to unveil their advancements, the industry waits in anticipation for new strategies that may redefine patient care across the globe.